A Phase 1 Study of Ziftomenib Plus Imatinib in People With Advanced Gastrointestinal Stromal Tumors

Full Title

A Phase 1a/1b Study of the Safety, Pharmacokinetics, and Antitumor Activity of the Oral Menin Inhibitor Ziftomenib in Combination with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors (GIST) After Imatinib Failure

Purpose

Researchers want to find the best dose of ziftomenib to give with imatinib in people with advanced gastrointestinal stromal tumors (GIST). The people in this study have GIST that keeps growing after treatment.

Ziftomenib blocks a protein pathway called the menin pathway, which plays an important role in cancer growth and survival. By blocking the menin pathway, ziftomenib may help slow or stop the growth of cancer cells. Ziftomenib and imatinib are both taken orally (by mouth).

Contact

For more information or to see if you can join this study, please call Dr. Mrinal Gounder’s office at 646-888-4167.